［1］Van Meerbeeck JP，Fennell DA，De Ruysscher DK.Small-cell lung cancer［J］.The Lancet，2011，378(4)：1741-1755.
［2］SHAO WP，WANG XW，LIU DR.Recent advances and future strategies for small cell lung cancer［J］.Chin J Lung Cancer，2017，20(6)：421-426.［邵为朋，王晓伟，刘德若.小细胞肺癌目前治疗的策略与未来方向［J］.中国肺癌杂志，2017，20(6)：421-426.］
［3］Detterbeck FC，Chansky K，Groome P，et al.The IASLC lung cancer staging project：methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming(eighth) edition of the TNM classification of lung cancer［J］.J Thorac Oncol，2016，11(9)：1433-1446.
［4］Neal JW，Gubens MA，Wakelee HA.Current management of small cell lung cancer［J］.Clin Chest Med，2011，32(4)：853-863.
［5］Tay FR，Pashley DH.Resin bonding to cervical sclerotic dentin：A review［J］.J Dent，2004，32(3)：173-196.
［6］Yoshiyama M，Sano H，Ebisu S，et al.Regional strengths of bonding agents to cervical sclerotic root dentin［J］.J Dental Res，1996，75(6)：1404-1413.
［7］Lally BE，Geigeg AM，Urbanic JJ，et al.Trends in the outcomes for patients with limited stage small cell lung cancer：An analysis of the surveillance，epidemiology and end results database［J］.Lung Cancer，2009，64(2)：226-231.
［8］Janssen-Heijnen ML，Maas HA，van de Schans SA，et al.Chemotherapy in elderly small cell lung cancer patients：Yes we can，but should we do it［J］？Ann Oncol，2011，22(4)：821-826.
［9］Hatfield LA，Haiden A，Lamont EB，et al.Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive stage small cell lung cancer in elderly patients［J］.J Oncol Pract，2016，12(7)：666-673.
［10］Laura C Caprario，David M Kent,Gary M Strauss，et al.Effects of chemotherapy on survial of elderly patients with small cell lung cancer：Analysis of the SEER-medicare database［J］.J Thorac Oncol，2013，8(10)：1272-1281.
［11］MA MJ，WANG MZ，XU Y，et al.First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute［J］.Chin J Lung Cancer，2014，17(1)：8-14.［马满娇，王孟昭，徐燕，等.单中心394例广泛期小细胞肺癌的一线化疗及生存分析［J］.中国肺癌杂志，2014，17(1)：8-14.］
［12］Sharma N，Pennell N，Nickolich M，et al.Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer［J］.Invest New Drugs，2014，32(2)：362-368.
［13］Abdelraouf F，Smit E，Hasan B，et al.Sunitinib（SU11248）in patients with chemo naive extensive small cell lung cancer or who have a "chemosensitive" relapse：A single arm phase Ⅱ study(EORTC-08061)［J］.Eur J Cancer，2016，54(1)：35-39.
［14］Trafalis DT，Alifieris C，Stathopoulos GP，et al.Phase Ⅱ study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer［J］.Cancer Chemother Pharmacol，2016，77(4)：713-722.
［15］Horn L，Mansfield AS，Szczesna A，et al.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer［J］.N Engl J Med，2018，379(23)：2220-2229.